Additionally, a 2023 study suggested that during the weight-loss phase of treatment ... patients taking a GLP-1 RA or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA, but few ...

REUTERS Eli Lilly’s drug is called “triple G” because it mimics GLP-1, the appetite-suppressing hormone GIP and glucagon, a hormone that helps control blood sugar levels. Phase 3 trials are ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have reported positive topline data from Hengrui’s Phase II obesity trial, considering an 8mg dose of the companies’ GLP-1/GIP receptor ...

--(BUSINESS WIRE)--Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted a third patent for inducing the secretion of GLP-1 and ...

Helicore’s two other developmental molecules are conjugates of a GLP-1 agonist peptide and a GIP antagonist antibody. “For these drugs, our question was that instead of going after one ...

Viking Therapeutics is expected to lead this group with its dual GLP-1RA/gastric inhibitory polypeptide receptor (GIP-R) agonist, VK-2735, which is in Phase II for obesity with an oral route of ...

Kailera unveiled the Zepbound-matching phase 2 data for KAI-9531 at the start of this year. As Fierce Biotech noted at the time, Zepbound—also a dual GIP and GLP-1 receptor agonist—showed ...

Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted a third patent for inducing the secretion of GLP-1 and GIP, in US patent US 12,171,727 B1 ...